ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
17.896,50
-0,14%
S&P 500
5.057,22
0,77%
Dow Jones
38.182,13
0,74%
Euro vs US Dollar
1,07245
0,06%
Bitcoin
59.307,94
1,84%
Registration Strip Icon for alerts Registrieren Sie sich für Echtzeit-Benachrichtigungen, benutzerdefinierte Portfolios und Marktbewegungen.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. Syndax Pharmaceuticals Inc (SNDX)

  7. Syndax Pharmaceuticals Inc (SNDX) News

SNDX Syndax Pharmaceuticals Inc

21,78
-0,19 (-0,86%)
Zuletzt aktualisiert: 21:38:30
Verzögert um 15 Minuten
Name Symbol Markt Aktientyp
Syndax Pharmaceuticals Inc SNDX NASDAQ Common Stock
  Änderung Änderung % Aktuell Zeit
Upgrade Icon
-0,19 -0,86% 21,78 21:38:30
Handelsbeginn Niedrig Hoch Schlusskurs Handelsende
22,11 21,50 22,33 21,97
more quote information »

Aktuelle News

Datum Zeit Quelle Überschrift
01.5.202413:00PRNUSSyndax to Announce First Quarter 2024 Financial Results and..
10.4.202422:05PRNUSSyndax Announces Participation at the Stifel 2024 Virtual..
08.4.202413:00PRNUSSyndax Presents Positive Pediatric Data from Pivotal..
05.4.202422:05PRNUSSyndax Pharmaceuticals Reports Inducement Grants Under..
28.3.202412:00PRNUSSyndax Announces Completion of Enrollment in AUGMENT-101..
26.3.202421:05PRNUSSyndax Announces FDA Priority Review of NDA for Revumenib..
18.3.202412:00PRNUSSyndax Announces Appointment of Steven Closter as Chief..
01.3.202422:05PRNUSSyndax Pharmaceuticals Reports Inducement Grants Under..
27.2.202423:28EDGAR2Form S-3ASR - Automatic shelf registration statement of..
27.2.202423:21EDGAR2Form S-8 - Securities to be offered to employees in employee..
27.2.202422:05PRNUSSyndax Pharmaceuticals Reports Fourth Quarter and Full Year..
27.2.202422:03EDGAR2Form 8-K - Current report
26.2.202413:00PRNUSSyndax Announces Participation at Two Upcoming Investor..
20.2.202422:05PRNUSSyndax to Announce Fourth Quarter and Year-end 2023..
14.2.202418:50EDGAR2Form SC 13G - Statement of acquisition of beneficial..
14.2.202413:01EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
14.2.202403:44EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
09.2.202422:05EDGAR2Form 4 - Statement of changes in beneficial ownership of..
09.2.202422:05EDGAR2Form 4 - Statement of changes in beneficial ownership of..
09.2.202422:05EDGAR2Form 4 - Statement of changes in beneficial ownership of..
09.2.202422:04EDGAR2Form 4 - Statement of changes in beneficial ownership of..
09.2.202422:04EDGAR2Form 4 - Statement of changes in beneficial ownership of..
09.2.202422:04EDGAR2Form 4 - Statement of changes in beneficial ownership of..
09.2.202422:04EDGAR2Form 4 - Statement of changes in beneficial ownership of..
02.2.202422:05PRNUSSyndax Pharmaceuticals Reports Inducement Grants Under..
01.2.202422:10PRNUSSyndax Announces Participation at Two Upcoming Investor..
05.1.202422:05PRNUSSyndax Pharmaceuticals Reports Inducement Grants Under..
02.1.202422:05PRNUSSyndax Announces Presentation at 42nd Annual J.P. Morgan..
02.1.202413:00PRNUSSyndax Highlights Recent Updates and Anticipated 2024..
20.12.202314:40EDGAR2Form 8-K - Current report
19.12.202322:16PRNUSSyndax Announces Closing of Public Offering of Common Stock..
15.12.202323:29EDGAR2Form 8-K - Current report
15.12.202323:29EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
15.12.202305:07PRNUSSyndax Announces Pricing of $200 Million Public Offering of..
14.12.202322:30EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
14.12.202322:00PRNUSSyndax Announces Proposed $150 Million Public Offering of..
12.12.202322:05EDGAR2Form 8-K - Current report
12.12.202318:00PRNUSSyndax Presents Positive Data from Pivotal AUGMENT-101 Trial..
11.12.202313:30PRNUSSyndax Announces Positive Data for Revumenib in Patients..
11.12.202312:33BWIncyte und Syndax präsentieren bei ASH-Plenarsitzung weitere..
10.12.202323:00BWIncyte and Syndax Present Additional Data from Positive..
04.12.202313:00PRNUSSyndax to Host Investor Event to Discuss Axatilimab and..
01.12.202322:05PRNUSSyndax Pharmaceuticals Reports Inducement Grants Under..
21.11.202315:00PRNUSSyndax Announces Data from Pivotal AUGMENT-101 Trial of..
07.11.202313:00PRNUSSyndax Announces Participation at Stifel Healthcare..
03.11.202321:05PRNUSSyndax Pharmaceuticals Reports Inducement Grants Under..
02.11.202321:05EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
02.11.202321:05PRNUSSyndax Pharmaceuticals Reports Third Quarter 2023 Financial..
02.11.202321:03EDGAR2Form 8-K - Current report
02.11.202314:00PRNUSSyndax Announces Results from the Pivotal AGAVE-201 Trial of..

Kürzlich von Ihnen besucht

NASDAQ
SNDX
Syndax Pharmaceuticals
Delayed Upgrade Clock
ADVFN Logo

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten